Immuneering Corp
IMRX
Company Profile
Business description
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Contact
245 Main Street
Second Floor
CambridgeMA02142
USAT: +1 617 500-8080
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
53
Stocks News & Analysis
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
stocks
12 picks for an income portfolio - Q1 2026 update
Passive income growth continues to exceed my target.
stocks
Strong guidance from undervalued ASX share
Shares surged after the announcement of first half fiscal 2026 guidance.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,174.10 | 12.00 | 0.13% |
| CAC 40 | 8,340.59 | 84.54 | -1.00% |
| DAX 40 | 24,372.60 | 329.64 | -1.33% |
| Dow JONES (US) | 49,447.43 | 868.71 | 1.79% |
| FTSE 100 | 10,611.03 | 56.60 | -0.53% |
| HKSE | 26,361.07 | 200.74 | 0.77% |
| NASDAQ | 24,468.48 | 365.78 | 1.52% |
| Nikkei 225 | 58,824.89 | 693.45 | -1.17% |
| NZX 50 Index | 12,915.45 | 150.61 | -1.15% |
| S&P 500 | 7,126.06 | 84.78 | 1.20% |
| S&P/ASX 200 | 8,953.30 | 13.60 | 0.15% |
| SSE Composite Index | 4,082.13 | 30.70 | 0.76% |